PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST)
- First Posted Date
- 2004-01-08
- Last Posted Date
- 2009-09-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 361
- Registration Number
- NCT00075218
- Locations
- 🇬🇧
Pfizer Investigational Site, Newcastle-Upon-Tyne, United Kingdom
Trial of Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine for the Treatment of Uncomplicated Malaria in India
Phase 2
Completed
- Conditions
- PLASMODIUM FALCIPARUM MALARIA
- First Posted Date
- 2003-12-24
- Last Posted Date
- 2011-05-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 230
- Registration Number
- NCT00074841
- Locations
- 🇮🇳
Pfizer Investigational Site, Indore, India
A Clinical Efficacy Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 Given In Combination With Chemotherapy
Phase 1
Completed
- Conditions
- Lung Neoplasms
- First Posted Date
- 2003-12-24
- Last Posted Date
- 2006-11-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 87
- Registration Number
- NCT00074854
- Locations
- 🇺🇸
Pfizer Investigational Site, Smyrna, Tennessee, United States
Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tube Cancer
Phase 2
Completed
- Conditions
- Ovarian NeoplasmsPeritoneal NeoplasmsFallopian Tube Neoplasms
- First Posted Date
- 2003-12-24
- Last Posted Date
- 2006-11-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 29
- Registration Number
- NCT00074867
- Locations
- 🇨🇦
Pfizer Investigational Site, Quebec, Canada
Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma
Phase 1
Completed
- Conditions
- Lymphoma, B-Cell
- Interventions
- Drug: Inotuzumab ozogamicin [CMC-544]
- First Posted Date
- 2003-12-05
- Last Posted Date
- 2018-12-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 79
- Registration Number
- NCT00073749
- Locations
- 🇩🇪
Universitaet Muenchen Klinikum Grosshadern, Muenchen, Germany
🇺🇸Northwestern Memorial Hospital, Chicago, Illinois, United States
🇺🇸UAB CCC Clinical Studies Unit, Birmingham, Alabama, United States
A Study to Evaluate the Efficacy and Safety of CP-101,606 in Subjects With an Acute Stroke
Phase 2
Terminated
- Conditions
- Stroke
- First Posted Date
- 2003-11-24
- Last Posted Date
- 2006-06-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 300
- Registration Number
- NCT00073476
- Locations
- 🇪🇸
Pfizer Investigational Site, Zaragoza, Spain
Irinotecan in Patients With Advanced Metastatic Breast Cancer Who Have Experienced Failure of an Anthracycline, a Taxane, and Capecitabine
Phase 2
Completed
- Conditions
- Breast Neoplasms
- First Posted Date
- 2003-11-13
- Last Posted Date
- 2008-10-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 134
- Registration Number
- NCT00072852
- Locations
- 🇳🇿
Pfizer Investigational Site, Wellington, New Zealand
AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS)
Phase 2
Completed
- Conditions
- Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome
- Interventions
- Drug: AG-013736 (Axitinib)
- First Posted Date
- 2003-10-13
- Last Posted Date
- 2012-06-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT00071006
- Locations
- 🇺🇸
Pfizer Investigational Site, Houston, Texas, United States
CPG 7909 Injection in Non-Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Carcinoma, Non-Small Cell Lung
- Interventions
- Drug: CPG 7909Drug: Chemotherapy
- First Posted Date
- 2003-10-08
- Last Posted Date
- 2009-02-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 116
- Registration Number
- NCT00070629
- Locations
- 🇺🇸
VA New Jersey Health Care System, East Orange, New Jersey, United States
🇨🇦Ottawa Regional Cancer Center, Ottawa, Ontario, Canada
🇩🇪Staedtisches Krankenhaus Martha-Maria, Halle-Dolau, Germany
CPG 7909 Injection in Melanoma
Phase 2
Completed
- Conditions
- Carcinoma, Melanoma
- Interventions
- First Posted Date
- 2003-10-08
- Last Posted Date
- 2009-02-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 184
- Registration Number
- NCT00070642
© Copyright 2025. All Rights Reserved by MedPath